Results 271 to 280 of about 56,913 (295)

Statin Regulation of CYP3A4 and CYP3A5 Expression

Pharmacogenomics, 2009
CYP3A4 and CYP3A5 are cytochrome P450 enzymes that are highly expressed in the liver and gut and metabolize endogenous compounds and xenobiotics. Statins are cholesterol-lowering drugs that are extensively metabolized by CYP3A4 and CYP3A5. The bioavailability of statins is affected by CYP3A4 and CYP3A5 and glucuronidases metabolism as well as uptake ...
Maria Alice Vieira, Willrich, Mario Hiroyuki, Hirata, Rosario Dominguez Crespo, Hirata   +2 more
openaire   +2 more sources

CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelicdependent manner

Int. Journal of Clinical Pharmacology and Therapeutics, 2015
CYP3A4*1G (G > A) in human CYP3A4 intron 10 is associated with therapeutic effects of CYP3A4-metabolized drugs. The aim of this study was to predict its function in the regulation of CYP3A4 expression.Functional analysis of the CYP3A4*1G allele was performed using bioinformatic methods and enhancer or promoter reporter assays in HepG2 cells ...
Weihong, Yang, Dengzhi, Zhao, Shengna, Han, Zengyuan, Tian, Liang, Yan, Guoqiang, Zhao, Quancheng, Kan, Wei, Zhang, Lirong, Zhang   +8 more
openaire   +2 more sources

Effects of Drug-Drug Interactions and CYP3A4 Variants on Alectinib Metabolism

Archives of Toxicology, 2023
Ren-Ai Xu, Jian-Ping Cai, Ya-Nan Liu
exaly  

Functional Evaluation of Cyclosporine Metabolism by CYP3A4 Variants and Potential Drug Interactions

Frontiers in Pharmacology, 2023
Guo-Xin Hu, Jianchang Qian, Bingbing Chen   +2 more
exaly  

CYP3A4 and the erythromycin breath test

Clinical Pharmacology & Therapeutics, 1998
openaire   +2 more sources

Pharmacokinetics of Midazolam in CYP3A4- and CYP3A5-Genotyped Subjects

European Journal of Clinical Pharmacology, 2004
Amalio Telenti, Clara Benzi Schmid, Pierre Baumann   +2 more
exaly  

The Barrier Function of CYP3A4 and P-Glycoprotein in the Small Bowel

Advanced Drug Delivery Reviews, 1997
Paul B Watkins
exaly  

Potent Mechanism-Based Inhibition of CYP3A4 by Imatinib Explains Its Liability to Interact With CYP3A4 Substrates

British Journal of Pharmacology, 2012
Anne M Filppula, Janne T. Backman, Pertti J. Neuvonen   +2 more
exaly  

CYP3A4*22: Promising Newly Identified CYP3A4 Variant Allele for Personalizing Pharmacotherapy

Pharmacogenomics, 2013
Vincent Haufroid, Teun van Gelder, Laure Elens   +2 more
exaly  

CYP3A4 Polymorphisms--Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review.

American Journal of Epidemiology, 2004
Ainsley Weston
exaly